Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review

被引：0
|
作者：
Mercedes Kile
Patcharaporn Sudchada
机构：
[1] University of Wisconsin-Madison,School of Pharmacy
[2] Naresuan University,Faculty of Pharmaceutical Sciences
来源：
International Urology and Nephrology | 2021年 / 53卷
关键词：
Chronic kidney disease; Anemia; Iron; ESA; Hypoxia-inducible factor prolyl hydroxylase inhibitors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：283 / 290
页数：7
相关论文
共 50 条
  • [31] Efficacy of Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitors in Renal Anemia: Enhancing Erythropoiesis and Long-Term Outcomes in Patients with Chronic Kidney Disease
    Yoshida, Yukina
    Takata, Tomoaki
    Taniguchi, Sosuke
    Kageyama, Kana
    Fujino, Yudai
    Hanada, Hinako
    Mae, Yukari
    Iyama, Takuji
    Hikita, Katsuya
    Isomoto, Hajime
    BIOMEDICINES, 2024, 12 (12)
  • [32] Initial experience of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with heart failure and renal anemia
    Nakamura, Makiko
    Imamura, Teruhiko
    Sobajima, Mitsuo
    Kinugawa, Koichiro
    HEART AND VESSELS, 2023, 38 (02) : 284 - 290
  • [33] The comparison of four hypoxia-inducible factor prolyl hydroxylase inhibitors on drug potency and cost for treatment in patients with renal anemia
    Imai, Enyu
    Imai, Atsuhiro
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2024, 28 (11) : 1090 - 1096
  • [34] The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease
    Zhong, Hongzhen
    Zhou, Tianbiao
    Li, Hongyan
    Zhong, Zhiqing
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 3003 - 3011
  • [35] Initial experience of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with heart failure and renal anemia
    Makiko Nakamura
    Teruhiko Imamura
    Mitsuo Sobajima
    Koichiro Kinugawa
    Heart and Vessels, 2023, 38 (2) : 284 - 290
  • [36] Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism
    Ogawa, Chie
    Tsuchiya, Ken
    Maeda, Kunimi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [37] Prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease
    Cases, A.
    Vera, M.
    Ojeda, R.
    Gorriz, J. L.
    DRUGS OF THE FUTURE, 2018, 43 (01) : 23 - 33
  • [38] Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis
    Li, Jing
    Xie, Qiong-Hong
    You, Li
    Xu, Ning-Xin
    Hao, Chuan-Ming
    PHARMACOLOGICAL RESEARCH, 2021, 163
  • [39] Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients
    Nangaku, Masaomi
    Farag, Youssef M. K.
    DeGoma, Emil
    Luo, Wenli
    Vargo, Dennis
    Khawaja, Zeeshan
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (07) : 1244 - 1252
  • [40] An Overview of Safety and Efficacy Between Hypoxia-Inducible Factor-Prolyl-Hydroxylase Inhibitors and Erythropoietin-Stimulating Agents in Treating Anemia in Chronic Kidney Disease Patients
    Sonia, Shamsun Nahar
    George, Sherie
    Shahi, Srushti R.
    Ali, Zahra
    Abaza, Abdelrahman
    Jamil, Aneeque
    Gutlapalli, Sai Dheeraj
    Ali, Marya
    Oble, Mrinal J. P.
    Yu, Ann Kashmer
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (07)
12345